Aryn del Valle, PA
Physician Assistant · Pensacola, FLNPI 1104475235
Payments from drug & device makers
Across 367 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$550
- Teva Pharmaceuticals USA, Inc.$485
- Novartis$450
- Jazz Pharmaceuticals Inc.$341
- SK Life Science, Inc.$239
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$150%
- Food & beverage$6,43499%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 161 | $2,380 |
| Pfizer | 32 | $550 |
| Teva Pharmaceuticals USA, Inc. | 23 | $485 |
| Novartis | 23 | $450 |
| Jazz Pharmaceuticals Inc. | 16 | $341 |
| SK Life Science, Inc. | 9 | $239 |
| Impel Pharmaceuticals Inc. | 10 | $211 |
| Octapharma USA, Inc. | 8 | $191 |
| Lilly USA, LLC | 10 | $165 |
| Axsome Therapeutics, Inc. | 7 | $133 |
| Lundbeck LLC | 5 | $110 |
| Tanabe Pharma America, Inc. | 5 | $93 |
| Argenx US, Inc. | 3 | $90 |
| Eisai Inc. | 4 | $89 |
| Amgen | 5 | $82 |
| AstraZeneca | 4 | $75 |
| Medtronic | 3 | $73 |
| Johnson & Johnson(2 entities) | 3 | $70 |
| Sunovion Pharmaceuticals Inc. | 5 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| GE HealthCare | 3 | $64 |
| Amneal Pharmaceuticals LLC | 3 | $62 |
| UCB, Inc. | 2 | $50 |
| Biogen | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Bristol Myers Squibb | 2 | $39 |
| Revance Therapeutics, Inc. | 1 | $29 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Genentech USA, Inc. | 1 | $25 |
| Adamas Pharmaceuticals, Inc. | 1 | $24 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $24 |
| Neurelis, Inc. | 1 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| MDD US Operations, LLC | 1 | $15 |
| Insightec,inc | 1 | $13 |
How this compares
$6,519 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 13 | $114,302 |
| NuplazidPimavanserin Tartrate | 13 | $65,012 |
| UbrelvyUbrogepant | 43 | $61,207 |
| GocovriAmantadine Hcl | 12 | $37,534 |
| Emgality PenGalcanezumab-Gnlm | 46 | $36,376 |
| QuliptaAtogepant | 23 | $32,127 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $30,238 |
| Nurtec OdtRimegepant Sulfate | 21 | $22,871 |
| FycompaPerampanel | 15 | $22,835 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 18 | $21,333 |
| NeuproRotigotine | 11 | $12,366 |
| RytaryCarbidopa/Levodopa | 13 | $11,782 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 18 | $6,420 |
| Sumatriptan Succinate | 65 | $4,187 |
| Levetiracetam | 62 | $3,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $48 | $114,30213 claims |
| AbbVieUbrelvy, Qulipta | $2,380 | $93,33466 claims |
| Acadia Pharmaceuticals IncNuplazid | $16 | $65,01213 claims |
| MDD US Operations, LLCGocovri | $15 | $37,53412 claims |
| PfizerNurtec Odt | $550 | $22,87121 claims |
| Eisai Inc.Fycompa | $89 | $22,83515 claims |
| UCB, Inc.Neupro | $50 | $12,36611 claims |
| Amneal Pharmaceuticals LLCRytary | $62 | $11,78213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Pensacola
- Christopher SmithPensacola$82K
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.